Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In a patient with Fuchs’ dystrophy and cataract, PK is the cornea technique of the past and ...

In a new study, researchers at the University of Oregon’s Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs’ ...

INDIANAPOLIS--(BUSINESS WIRE)--Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use of an experimental drug treatment in ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a ...